Lupin Limited (LUPIN) — Announcement | 20 August 2026

20 August 2026 · NSE Neutral

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

📢 Key Event

Lupin's Dutch subsidiary secures exclusive EU licensing rights for YUVEZZI eye drop.

🔄 What Changed

Added exclusive commercialization rights for YUVEZZI in five European markets.

🔮 What's Next

Initial term lasts 20 years from first commercial sale, renewable in 5-year increments at VISUfarma's discretion.

💡 Investor Takeaway

This partnership strengthens Lupin's ophthalmology portfolio and offers long-term growth potential in Europe.

Lupin announced that its Dutch subsidiary VISUfarma entered an exclusive license agreement with Visus Therapeutics to commercialize YUVEZZI, a dual-agent eye drop for presbyopia, across the European Union, United Kingdom, Switzerland, Norway, and Iceland. The deal includes up to €75 million in potential consideration, comprising a €20 million strategic investment via SAFE and €55 million in milestone payments, with royalties on future sales. This expands Lupin’s specialty ophthalmology portfolio and creates long-term growth opportunities in a key therapeutic segment.

📄 View Original Announcement (PDF)

📊 Stock Analysis — LUPIN ✨ Ask AI About This

About Lupin Limited (LUPIN)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹94,274.49 CrP/E: 16.6ROE: 24.6%ROCE: 27.9%Div Yield: 0.87%

View full LUPIN stock details →

📡 Get AI alerts when LUPIN files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track LUPIN — Free

💡 Ask AI about this filing

"How will the €75M potential consideration be structured?""What are the specific regulatory milestones for YUVEZZI in Europe?""When will YUVEZZI generate its first commercial sales in the EU?"

Ask AI Free →

📊 More LUPIN filings

🔴 Announcement — 28 September 2026Lupin announced that its U.S. subsidiary received tentative FDA approval for a novel apixaban oral s...
Announcement — 28 September 2026Lupin Ltd announced that its insider trading window will close on October 1, 2026, and remain shut u...
🔴 Corporate Action — 21 September 2026Lupin announced on September 21, 2026, the allotment of 24,111 fully paid-up equity shares of ₹2 eac...
🔴 Announcement — 8 September 2026Lupin Ltd announced its participation in two upcoming investor events: the Kotak Healthcare Conferen...
🔴 Announcement — 4 September 2026Lupin announced that the U.S. FDA approved its ANDA for Modafinil Tablets USP 100 mg and 200 mg, mar...

See all LUPIN filings →

🔥 Also filed on 20 August 2026

JSLLJeena Sikho Lifecare LimitedFinancial Results ANURASAnupam Rasayan India LimitedFinancial Results NIRAJNiraj Cement Structurals LimitedAnnouncement PNBHOUSINGPNB Housing Finance LimitedCorporate Action KRONOXKronox Lab Sciences LimitedAnnouncement SUPRAJITSuprajit Engineering LimitedAnnual Report

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when LUPIN files new disclosures

Track LUPIN filings, board meetings, and corporate actions. Free email alerts at 5 PM.